In the second quarter of 2024, the company reported sales of $22.4 billion, up by 4.3%. Xarelto, Stelara, and Imbruvica accounted for 19% of the company's revenue in the second quarter of 2024. Johnson & Johnson (NYSE:JNJ) also saw success with regulatory approvals for some medications such as RYBREVANT and TREMFYA. Johnson & Johnson (NYSE:JNJ) is dominant in the oncology sector, with sales growing by 16% to reach $5.09 billion. This was attributable to the massive success of its cancer drug, Darzalex.